# A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

> **NCT00499239** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 32 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Chronic Lymphocytic Leukemia
- Multiple Myeloma

## Interventions

- **DRUG:** GS-9219

## Key facts

- **NCT ID:** NCT00499239
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-10
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Unacceptable safety profile
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499239, "A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00499239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*